Leadership

David Adams is a Senior Group Leader at the Wellcome Sanger Institute with an interest in functional genomics, genetic screens, cancer models and drug discovery. He is also interested in cancer predisposition and works extensively with investigators in low and middle income countries, particularly in Latin America.

Dr. Bolognesi is a Group Leader at the Institute for Bioengineering of Catalonia (IBEC). She trained in biophysics at the University of Cambridge and in genomics at the Center for Genomic Regulation. Her lab develops scalable assays that report both on folded and intrinsically disordered proteins, with the ultimate goal of understanding functional and pathological protein aggregation.

Dr. Fowler is a Professor of Genome Sciences and Director of the Center for the Multiplexed Assessment of Phenotype at the University of Washington. Dr. Fowler is a leader in high-throughput, sequencing-based assays, and his lab has developed foundational technologies for interrogating the effect of human genetic variants. He is now working to understand the effects of the millions of variants found in a typical human genome.

Dr. Gallego Romero is the Head of human genomics and evolution at St. Vincent’s Institute of Medical Research. Her work focuses on genetic differences between human populations, personalized medicine, and global health equity. Irene’s lab combines functional genomics with the versatility of induced pluripotent stem cells to address questions about the mechanisms of evolutionary adaptation in humans.

Anna Gloyn is currently Professor of Pediatrics and Genetics at Stanford University. She trained at the Universities of Oxford, Exeter and Pennsylvania. The consistent focus of her research has been using naturally occurring mutations in humans as tools to identify critical regulatory pathways and insights into normal physiology and to translate this information into improvements in clinical care.
(Full: Anna Gloyn is currently Professor of Pediatrics and by Courtesy Genetics at Stanford University. The consistent focus of her research has been using naturally occurring mutations in humans as tools to identify critical regulatory pathways and insights into normal physiology and to translate this information into improvements in clinical care. Anna's research is focused on diabetes and includes both monogenic varieties and type 2 diabetes. Her group uses a variety of complementary approaches working both a scale (genome-wide) and specific loci and includes human genetics, functional genomics, physiology and islet-biology to dissect out the molecular mechanisms driving disease pathogenesis. She is involved in a number of international efforts to interpret variation in genes with known roles in monogenic diabetes and is a member of the Clin Gen Monogenic Diabetes Variant Curation Expert Panel and the American Diabetes Association Precision Medicine Consensus Working Group for Precision Diagnostics for Monogenic Diabetes).

Matthew Hurles is Director of the Wellcome Sanger Institute and leads a research group focused on deciphering the genetic causes of severe developmental disorders, and understanding how DNA mutates as it is passed from generation to generation.

My research focuses on understanding both the causes and consequences of molecular variation in the human brain and the role this plays in dementia and neuropsychiatric disorders. My group is interested in the dynamic genomic processes occurring in the human brain during development and aging, exploring interactions between the epigenome, environment and DNA sequence variation. Using cutting-edge genomics methods, we aim to undertake an integrated genetic-epigenetic approach to disease, incorporating genetic, transcriptional and epigenomic variation. We led the first large-scale epigenomic studies of Alzheimer’s disease, and are currently investigating genomic changes in individual brain cells.

Roth trained in physics and biology at UC Berkeley and Harvard. He chairs the Department of Computational and Systems Biology at the University of Pittsburgh. His group is combining experimental and computational methods to systematically map the context-dependent impacts of human sequence variation.

Dr Alan Rubin is a Group Leader in the Collaborative Centre for Genomic Cancer Medicine, a joint venture of the University of Melbourne and Peter MacCallum Cancer Centre. He earned his PhD in Genome Sciences from the University of Washington before moving to the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia. Alan’s work focuses on developing new tools and approaches to analyse, share and interpret high-throughput functional genomics data.

Dr. Starita is an Assistant Professor. in the Department of Genome Sciences at the University of Washington and the Co-director of Brotman Baty Advanced Technology Lab. She earned her Ph.D. from Harvard Medical School before coming to the University of Washington to train in functional genomics with Stan Fields and Jay Shendure.